| URL: | http://bio-bigdata.hrbmu.edu.cn/CiTSA |
| Full name: | Cancer immunoTherapy Signature Atlas |
| Description: | CiTSA, a comprehensive resource, which can provide a wealth of information about experimentally supported cancer immunotherapy signatures and also provide analysis tools based on single cell and bulk datasets. CiTSA stores 878 entries of experimentally supported associations between 412 signatures and 177 treatments of five mian immunotherapy categories across 30 cancer types. |
| Year founded: | 2023 |
| Last update: | 2023 |
| Version: | v1.0 |
| Accessibility: |
Accessible
|
| Country/Region: | China |
| Data type: | |
| Data object: | |
| Database category: | |
| Major species: | |
| Keywords: |
| University/Institution: | Harbin Medical University |
| Address: | College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China |
| City: | |
| Province/State: | |
| Country/Region: | China |
| Contact name (PI/Team): | Xia Li |
| Contact email (PI/Helpdesk): | lixia@hrbmu.edu.cn |
|
CiTSA: a comprehensive platform provides experimentally supported signatures of cancer immunotherapy and analysis tools based on bulk and scRNA-seq data. [PMID: 36912931]
Immunotherapy has greatly changed the status of cancer treatment, and many patients do not respond or develop acquired resistance. The related research is blocked by lacking of comprehensive resources for researchers to discovery and analysis signatures, then further exploring the mechanisms. Here, we first offered a benchmarking dataset of experimentally supported signatures of cancer immunotherapy by manually curated from published literature works and provided an overview. We then developed CiTSA ( http://bio-bigdata.hrbmu.edu.cn/CiTSA/ ) which stores 878 entries of experimentally supported associations between 412 signatures such as genes, cells, and immunotherapy across 30 cancer types. CiTSA also provides flexible online tools to identify and visualize molecular/cell feature and interaction, to perform function, correlation, and survival analysis, and to execute cell clustering, cluster activity, and cell-cell communication analysis based on single cell and bulk datasets of cancer immunotherapy. In summary, we provided an overview of experimentally supported cancer immunotherapy signatures and developed CiTSA which is a comprehensive and high-quality resource and is helpful for understanding the mechanism of cancer immunity and immunotherapy, developing novel therapeutic targets and promoting precision immunotherapy for cancer. |